Revista de Psiquiatría del uruguay, Год журнала: 2021, Номер 85(1)
Опубликована: Окт. 1, 2021
Frontiers in Psychiatry, Год журнала: 2023, Номер 14
Опубликована: Май 19, 2023
Background Schizophrenia affects about 1% of the global population. In addition to complex etiology, linking this illness genetic, environmental, and neurobiological factors, dynamic experiences associated with disease, such as delusions, hallucinations, disorganized thinking, abnormal behaviors, limit neurological consensuses regarding mechanisms underlying disease. Methods study, we recruited 72 patients schizophrenia 74 healthy individuals matched by age sex investigate structural brain changes that may serve prognostic biomarkers, indicating evidence neural dysfunction subsequent cognitive behavioral deficits. We used voxel-based morphometry (VBM) determine these in three tissue structures: gray matter (GM), white (WM), cerebrospinal fluid (CSF). For both image processing statistical analysis, parametric mapping (SPM). Results Our results show exhibited a significant volume reduction GM WM. particular, reductions were more evident frontal, temporal, limbic, parietal lobe, similarly WM predominantly limbic lobe. addition, demonstrated increase CSF left third lateral ventricle regions. Conclusion This VBM study supports existing research showing is alterations structure, including matter, volume. These findings provide insights into neurobiology inform development effective diagnostic therapeutic approaches.
Язык: Английский
Процитировано
23
Expert Review of Clinical Pharmacology, Год журнала: 2022, Номер 15(1), С. 65 - 78
Опубликована: Янв. 2, 2022
Introduction Pharmacovigilance studies have definitely established that clozapine can cause myocarditis. Two published reviews suggested on rare occasions other antipsychotics may induce myocarditis.Areas covered This review explored myocarditis associated with than by conducting a systematic search of the literature and critically analyzing current data in VigiBase compared to clozapine-associated is World Health Organization's global pharmacovigilance database uses statistical signal for associations logarithmic measure disproportionality called information component (IC).Expert opinion For quetiapine, provided 106 reports significant (IC = 1.8; IC025 1.5) which was confounded 48% (51/106) co-prescription. Combining cases five probable during quetiapine monotherapy (4 after overdose or rapid titration). olanzapine, 107 2.1; 1.8) probably explained 77% (82/107) using one case olanzapine monotherapy. another three therapy titration high dose.
Язык: Английский
Процитировано
31
Asian Journal of Psychiatry, Год журнала: 2021, Номер 63, С. 102744 - 102744
Опубликована: Июль 15, 2021
Monopharmacy with antipsychotics and antidepressants is the first-line treatment for schizophrenia major depressive disorder (MDD) in most clinical guidelines, while polypharmacy psychotropic agents of common practice. There are no detailed data on prescription patterns inpatients mental illness reliable diagnoses made by treating psychiatrists. We gathered at discharge from 2177 patients 1238 MDD October 2016 to March 2018. The aged between 60 79 were prescribed lower doses hypnotics/anxiolytics than those 40 59. significant differences rate that MDD. frequency concomitant drugs such as anti-Parkinson drugs, anxiolytics/hypnotics mood stabilizers subjects antipsychotic was significantly higher monotherapy. For schizophrenia, olanzapine, risperidone, aripiprazole, quetiapine, blonanserin five antipsychotics. MDD, mirtazapine, duloxetine, escitalopram, trazodone sertraline antidepressants. Our results showed use high antipsychotics, percentages concurrent schizophrenia. Notably, these collected before intensive instruction regarding guidelines; therefore, we need assess change pattern post guideline instruction.
Язык: Английский
Процитировано
33
Frontiers in Psychiatry, Год журнала: 2021, Номер 12
Опубликована: Ноя. 24, 2021
Antipsychotic polypharmacy/drug combination treatment (APP) is a remarkably common practice in the schizophrenia context, given lack of general support Guidelines. There also vast literature on APP outcomes, but paucity high-quality evidence-based data to guide and optimize adequate use APP. This seems particularly true regarding many pharmacology-based considerations involved strategies. paper first briefly summarizes clinical related Against this backdrop, pharmacological target profile features are then described frequently used antipsychotic agents, relation estimated free plasma exposure levels at clinically efficacious dosing. strategies based properties these drugs scrutinized gauged within background framework. The anticipated usefulness from standpoint detailed efficacy, adverse effect (AE)/tolerability, safety perspective, including why, when, how it may be its advantage. For purpose, number theoretically beneficial combinations as well instances with suboptimal-and even futile-APP approaches exemplified discussed rational pharmacodynamic pharmacokinetic pros cons point-of-view. In exposé, particular attention paid utility 3rd Generation dopamine (DA) D2-D3 agonists an setting.
Язык: Английский
Процитировано
18
Brain Sciences, Год журнала: 2024, Номер 14(5), С. 433 - 433
Опубликована: Апрель 26, 2024
Up to 34% of patients with schizophrenia are resistant several treatment trials. Lack continuous and adequate is associated relapse, rehospitalization, a lower effect antipsychotic therapy, higher risk side effects. Long-acting injectables antipsychotics (LAI APs) enhance compliance improve clinical outcomes quality life in schizophrenia, thus it may be advisable administer two LAI APs at the same time cases treatment-resistant schizophrenia. The purpose this review summarize available literature regarding combined use or other psychotic spectrum disorders.
Язык: Английский
Процитировано
2
International Clinical Psychopharmacology, Год журнала: 2022, Номер 38(3), С. 160 - 168
Опубликована: Дек. 16, 2022
The present cross-sectional, retrospective study aimed to assess the prevalence of cardiovascular disease (CVD) risk factors and metabolic syndrome in a sample psychiatric patients treated with long-acting injectable antipsychotics (LAIs). clinical charts 120 patients, mainly diagnosed schizophrenia (30.0%), schizoaffective disorder (15.0%), bipolar (13.3%) on LAIs therapy – initiated period from 2013 2019 lasting at least one year were retrospectively reviewed related socio-demographic, laboratory variables collected. 70.8% first-generation LAIs, remaining 29.2% second-generation LAIs. overall showed low compliance performing required exams evaluations CVD factors. was 30.8%, and, considering specific factors, 55% total reported abdominal obesity, 43.3% arterial hypertension, 41.7% HDL-cholesterol, 25.8% hypertriglyceridemia, 20.8% fasting hyperglycemia. Lastly, 6.7% prolonged corrected QT (QTc) interval ECG. Patients should be regularly monitored for changes Metabolic rapidly develop after initiating an antipsychotic these often involve parameters, that can easily recorded outpatient setting (e.g. obesity hypertension).
Язык: Английский
Процитировано
8
BMC Psychiatry, Год журнала: 2023, Номер 23(1)
Опубликована: Июнь 28, 2023
Abstract Background Polypharmacy of additional psychotropics alongside the main treatment drug (antipsychotics in schizophrenia and antidepressants major depressive disorder) is common Japan. Our goal to align psychotropic prescription Japan with international standards, while reducing differences between facilities. To achieve this goal, we aimed compare prescriptions at time hospital admission discharge. Methods Data on discharge from 2016 2020 were collected. We divided patients into four groups: (1) mono_mono group, monotherapy discharge; (2) mono_poly polypharmacy (3) poly_poly (4) poly_mono compared changes dosage number among groups. Results For both disorder, who received likely receive vice versa. schizophrenia, was prescribed more often group than that group. The not changed all for 10% patients. Conclusions It critical avoid a regimen ensure guideline-compliant provided. expect higher rates after EGUIDE lectures. Trial registration study protocol registered University Hospital Medical Information Network Registry (UMIN000022645).
Язык: Английский
Процитировано
4
Clinical Psychopharmacology and Neuroscience, Год журнала: 2021, Номер 19(4), С. 600 - 609
Опубликована: Окт. 25, 2021
Other SectionsAbstractINTRODUCTIONWHEN AND HOW TO INITIATE APP?TOTAL NUMBER OF APP OR TOTAL DAILY DOSE APP, WHICH IS MORE PROBLEMATIC?IS INSIGHT ONE ISSUES IN THE USE APP?IS THERE ANY BEST-AVAILABLE REGIMEN FOR TREATMENT SCHIZOPHRENIA?HOW LONG SHOULD WE MAINTAIN ROUTINE PRACTICE?HOW SWITCH APM CLINICAL PRACTICE?DISCUSSIONConflicts of InterestAuthor ContributionsTablesReferences
Язык: Английский
Процитировано
8
Опубликована: Янв. 1, 2023
Schizophrenia (ScZ) is a mental condition in which individuals' views of reality are distorted. Hallucinations, delusions, altered cognition, and behavior some the symptoms ScZ, making it challenging to deal with daily life. Recognizing clinical manifestations ScZ early essential. It caused by genetic factors, alterations neurotransmitter system, mitochondrial dysfunction, immunological variables, psychological issues. Apart from these causes, traumatic events childhood or particularly cannabis consumption during adolescence (a critical phase development brain) may influence disease's origin, progression, relapse risk. Initiating treatment immediately after initial episode psychosis important for recovery. The patients usually require long-term treatment. There multiple medications available treating managing associated ScZ. These medicines have been shown ameliorate related However, several drugs show adverse side effects. This chapter discusses well-known mechanism action, emerging compounds that can be used treat effectively. Curcumin, emodin, stigmasterol, spinach, vitamins, exogenous melatonin, cannabidiol, among other developing medicines, all proven linked schizophrenia.
Язык: Английский
Процитировано
3
Scientific Reports, Год журнала: 2021, Номер 11(1)
Опубликована: Июнь 29, 2021
Abstract Schizophrenia is a chronic mental condition presenting wide range of symptoms. Although it has low prevalence compared to other conditions, negative impact on social and occupational functions. This study aimed assess the appropriateness antipsychotic medications administered schizophrenic patients describe current treatment patterns for schizophrenia. A retrospective cohort was conducted in all over age 15 with an active diagnosis schizophrenia treated antipsychotics between 2008 2013 Valencia region. total 19,718 were eligible inclusion. The main outcome assessed inappropriateness pharmacotherapeutic management, including polypharmacy use. Altogether, 30.4% received polypharmacy, 6.8% prescribed three or more antipsychotics. Overdosage affected 318 individuals (1.6%), 21.5% used concomitant psychotropics without associated psychiatric diagnosis. Women people comorbid like anxiety depression less likely receive polypharmacy. In contrast, increased psychoactive drugs, only user maintenance therapy, visits health hospital. Overall, we observed high level prescriptions. Greater adherence guidelines could maximize benefits while minimizing risk adverse effects.
Язык: Английский
Процитировано
5